Closing in on Cancer

At Merus, we are clinically advancing leading-edge, targeted treatments to address the unmet needs of patients with various types of cancer. Utilizing our proprietary technology platforms, we are developing innovative multispecific antibody therapeutics, referred to as Multiclonics®.

Multispecific
antibody
platform

Our Multiclonics® therapeutics are full-length human IgG bispecific (Biclonics®) and trispecific (Triclonics™) antibodies that bind to multiple targets, and are manufactured with advantageous features for anti-cancer effects against the complex mechanisms that drive cancer. Multiclonics® are capable of being developed with industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.

 

Established
clinical
pipeline

Our therapeutic candidates engage cancer antigens and harness the power of the immune system to kill tumor cells in unique and powerful ways by utilizing our proprietary technology platform and deep expertise in oncology. We are currently developing a broad pipeline of wholly owned and licensed Biclonics® drug candidates in the clinic with compelling target combinations and unique mechanisms of action.

 

Lead
candidate
targeting
NRG1

Our most advanced cancer drug candidate is zenocutuzumab (Zeno), a Biclonics® antibody with a HER2/HER3 target combination directed at NRG1 fusions, a rare and powerful driver of cancer cell growth. Zeno has shown encouraging early clinical activity in patients with solid tumors harboring neuregulin 1 (NRG1) fusions including lung, pancreatic and other types of solid tumors.